Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Antituberculosis Drugs
share announcement

Antituberculosis Drugs

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 August 2012) | Viewed by 56139

Special Issue Editor

Prof. Dr. Marcelo J. Nieto

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62026-2000, USA
Interests: drug design; parallel synthesis; anti-infective drugs; natural products; antivirals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Tuberculosis (TB), a disease cause by Mycobacterium tuberculosis (Mt), is one of the deadliest infectious diseases. Each year almost 2 million people die worldwide according to estimates from the World Health Organization (WHO). The treatment for tuberculosis is more than 30 years old and includes a multidrug approach during a long period of time (6-9 months). There are several resistant strains of Mt including multidrug (MDR) strains resistant to more than one first line drugs and extremely resistant strains (XDR), resistant to first and second line drugs. These strains have made Mt and TB very difficult to treat and eradicate. This special issue will focus on the biology of Mt, resistance, new targets, drug discovery and development, and clinical trials.

Dr. Marcelo J. Nieto
Guest Editor

Keywords

  • Mycobacterium tuberculosis
  • TB resistance
  • drug discovery
  • mode of action
  • clinical trials
  • drug development
  • opportunistic infections

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

506 KiB  
Article
Metabolism and Pharmacokinetics of the Anti-Tuberculosis Drug Ethionamide in a Flavin-Containing Monooxygenase Null Mouse
by Amy L. Palmer, Virginia L. Leykam, Andrew Larkin, Sharon K. Krueger, Ian R. Phillips, Elizabeth A. Shephard and David E. Williams
Pharmaceuticals 2012, 5(11), 1147-1159; https://doi.org/10.3390/ph5111147 - 25 Oct 2012
Cited by 15 | Viewed by 8991
Abstract
Multiple drug resistance (MDR) in Mycobacterium tuberculosis (mTB), the causative agent for tuberculosis (TB), has led to increased use of second-line drugs, including ethionamide (ETA). ETA is a prodrug bioactivated by mycobacterial and mammalian flavin-containing monooxygenases (FMOs). FMO2 is the major isoform in [...] Read more.
Multiple drug resistance (MDR) in Mycobacterium tuberculosis (mTB), the causative agent for tuberculosis (TB), has led to increased use of second-line drugs, including ethionamide (ETA). ETA is a prodrug bioactivated by mycobacterial and mammalian flavin-containing monooxygenases (FMOs). FMO2 is the major isoform in the lungs of most mammals, including primates. In humans a polymorphism exists in the expression of FMO2. FMO2.2 (truncated, inactive) protein is produced by the common allele, while the ancestral allele, encoding active FMO2.1, has been documented only in individuals of African and Hispanic origin, at an incidence of up to 50% and 7%, respectively. We hypothesized that FMO2 variability in TB-infected individuals would yield differences in concentrations and ratios of ETA prodrug and metabolites. In this study we assessed the impact of the FMO2 genetic polymorphism on the pharmacokinetics of ETA after administration of a single oral dose of ETA (125 mg/kg) to wild type and triple Fmo1/2/4-null mice, measuring levels of prodrug vs. metabolites in plasma collected from 0 to 3.5 h post-gavage. All mice metabolized ETA to ETA S-oxide (ETASO) and 2-ethyl-4-amidopyridine (ETAA). Wild type mice had higher plasma concentrations of metabolites than of parent compound (p = 0.001). In contrast, Fmo1/2/4-null mice had higher plasma concentrations of parent compound than of metabolites (p = 0.0001). Thus, the human FMO2 genotype could impact the therapeutic efficacy and/or toxicity of ETA. Full article
(This article belongs to the Special Issue Antituberculosis Drugs)
►▼ Show Figures

Figure 1

179 KiB  
Article
The Chemical Components of Sesbania grandiflora Root and Their Antituberculosis Activity
by Noviany Hasan, Hasnah Osman, Suriyati Mohamad, Wong Keng Chong, Khalijah Awang and Anis Safirah Mohd Zahariluddin
Pharmaceuticals 2012, 5(8), 882-889; https://doi.org/10.3390/ph5080882 - 23 Aug 2012
Cited by 62 | Viewed by 13007
Abstract
Three isoflavanoids, isovestitol (1), medicarpin (2), and sativan (3), along with another known compound, betulinic acid (4), were isolated from the root of Sesbania grandiflora. The structures of the isolated compounds were characterised by means of spectroscopic techniques (UV, IR, MS, 1 [...] Read more.
Three isoflavanoids, isovestitol (1), medicarpin (2), and sativan (3), along with another known compound, betulinic acid (4), were isolated from the root of Sesbania grandiflora. The structures of the isolated compounds were characterised by means of spectroscopic techniques (UV, IR, MS, 1H- and 13C-NMR, DEPT, COSY, HMQC, HMBC, and MS analysis). All the tested compounds 1–4 exhibited antituberculosis activity against Mycobacterium tuberculosis H37Rv, with MIC values of 50 µg/mL for compounds 1–3, and 100 µg/mL for compound 4, whereas, the methanol extract exhibited antituberculosis activity of 625 µg/mL. This is the first report on the occurrence of isoflavonoids in this plant and their antituberculosis activity. Full article
(This article belongs to the Special Issue Antituberculosis Drugs)
►▼ Show Figures

Figure 1

Review

Jump to: Research

517 KiB  
Review
The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance
by Jansy Passiflora Sarathy, Véronique Dartois and Edmund Jon Deoon Lee
Pharmaceuticals 2012, 5(11), 1210-1235; https://doi.org/10.3390/ph5111210 - 9 Nov 2012
Cited by 83 | Viewed by 16401
Abstract
In the fight against tuberculosis, cell wall permeation of chemotherapeutic agents remains a critical but largely unsolved question. Here we review the major mechanisms of small molecule penetration into and efflux from Mycobacterium tuberculosis and other mycobacteria, and outline how these mechanisms may [...] Read more.
In the fight against tuberculosis, cell wall permeation of chemotherapeutic agents remains a critical but largely unsolved question. Here we review the major mechanisms of small molecule penetration into and efflux from Mycobacterium tuberculosis and other mycobacteria, and outline how these mechanisms may contribute to the development of phenotypic drug tolerance and induction of drug resistance. M. tuberculosis is intrinsically recalcitrant to small molecule permeation thanks to its thick lipid-rich cell wall. Passive diffusion appears to account for only a fraction of total drug permeation. As in other bacterial species, influx of hydrophilic compounds is facilitated by water-filled open channels, or porins, spanning the cell wall. However, the diversity and density of M. tuberculosis porins appears lower than in enterobacteria. Besides, physiological adaptations brought about by unfavorable conditions are thought to reduce the efficacy of porins. While intracellular accumulation of selected drug classes supports the existence of hypothesized active drug influx transporters, efflux pumps contribute to the drug resistant phenotype through their natural abundance and diversity, as well as their highly inducible expression. Modulation of efflux transporter expression has been observed in phagocytosed, non-replicating persistent and multi-drug resistant bacilli. Altogether, M. tuberculosis has evolved both intrinsic properties and acquired mechanisms to increase its level of tolerance towards xenobiotic substances, by preventing or minimizing their entry. Understanding these adaptation mechanisms is critical to counteract the natural mechanisms of defense against toxic compounds and develop new classes of chemotherapeutic agents that positively exploit the influx and efflux pathways of mycobacteria. Full article
(This article belongs to the Special Issue Antituberculosis Drugs)
►▼ Show Figures

Figure 1

200 KiB  
Review
Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
by Leonard Amaral and Joseph Molnar
Pharmaceuticals 2012, 5(9), 1021-1031; https://doi.org/10.3390/ph5091021 - 17 Sep 2012
Cited by 10 | Viewed by 6931
Abstract
This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper [...] Read more.
This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries. Full article
(This article belongs to the Special Issue Antituberculosis Drugs)
►▼ Show Figures

Figure 1

227 KiB  
Review
Chemotherapeutic Interventions Against Tuberculosis
by Neeraj Shakya, Gaurav Garg, Babita Agrawal and Rakesh Kumar
Pharmaceuticals 2012, 5(7), 690-718; https://doi.org/10.3390/ph5070690 - 28 Jun 2012
Cited by 31 | Viewed by 9864
Abstract
Tuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently [...] Read more.
Tuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently available agents are complicated by serious side effects, drug interactions and long-term administration. This has prompted urgent research efforts in the discovery and development of new anti-tuberculosis agent(s). Several families of compounds are currently being explored for the treatment of tuberculosis. This review article presents an account of the existing chemotherapeutics and highlights the therapeutic potential of emerging molecules that are at different stages of development for the management of tuberculosis disease. Full article
(This article belongs to the Special Issue Antituberculosis Drugs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop